Related Experiment Videos

Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease

Pedro A Lemos1, Pim J de Feyter, Patrick W Serruys

  • 1Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.

International Journal of Cardiology
|February 15, 2005
PubMed

Insights

Multivessel coronary artery disease increases cardiac event risk after percutaneous coronary intervention. Fluvastatin treatment significantly reduced this increased risk, improving long-term outcomes in the Lescol Intervention Prevention Study (LIPS).

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Pharmacology

Background:

  • The Lescol Intervention Prevention Study (LIPS) investigated long-term cardiac atherosclerotic complications.
  • Impact of coronary artery disease extent (single- vs. multivessel) and fluvastatin treatment were evaluated.

Purpose of the Study:

  • To assess the influence of single-vessel versus multivessel coronary disease on long-term cardiac outcomes post-percutaneous coronary intervention (PCI).
  • To determine the effect of fluvastatin treatment on these outcomes, particularly in patients with multivessel disease.

Main Methods:

  • 1063 patients with single-vessel disease and 614 with multivessel disease underwent randomization.
  • Patients received either fluvastatin (40 mg twice daily) or placebo for at least 3 years post-PCI.
  • Incidence of cardiac death, non-fatal myocardial infarction, and coronary re-interventions were assessed.

Main Results:

  • Multivessel disease significantly increased cardiac event risk compared to single-vessel disease in the placebo group (RR 1.67).
  • Patients with multivessel disease had higher baseline cardiovascular risk factors.
  • In the fluvastatin-treated group, no significant difference in long-term outcomes was observed between single-vessel and multivessel disease patients (RR 1.28).

Conclusions:

  • Multivessel coronary artery disease negatively impacts 4-year outcomes following PCI.
  • Long-term fluvastatin treatment effectively mitigated the increased risk associated with multivessel coronary disease.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...